


a 50 mg versus 100 mg

Study or Subgroup	50 mg		100 mg		Weight	Risk Ratio
	Events	Total	Events	Total		M-H, Random, 95% CI
Färkkilä M et al., 2012	53	82	59	82	46.9%	0.90 [0.73, 1.11]
Goadsby PJ et al., 2019	166	654	229	635	53.1%	0.70 [0.60, 0.83]
Total (95% CI)		736		717	100.0%	0.79 [0.61, 1.02]
Total events	219		288			


Heterogeneity: Tau² = 0.02; Chi² = 3.55, df = 1 (P = 0.06); I² = 72%
 Test for overall effect: Z = 1.84 (P = 0.07)



b 100 mg versus 200 mg

Study or Subgroup	100 mg		200 mg		Weight	Risk Ratio
	Events	Total	Events	Total		M-H, Fixed, 95% CI
Färkkilä M et al., 2012	59	82	61	71	11.3%	0.84 [0.71, 0.99]
Goadsby PJ et al., 2019	229	635	253	649	43.1%	0.93 [0.80, 1.07]
Kuca B et al., 2018	229	630	260	609	45.6%	0.85 [0.74, 0.98]
Total (95% CI)		1347		1329	100.0%	0.88 [0.81, 0.96]
Total events	517		574			

Heterogeneity: Chi² = 1.06, df = 2 (P = 0.59); I² = 0%
 Test for overall effect: Z = 2.75 (P = 0.006)



c 200 mg versus 50 mg

Study or Subgroup	50 mg		200 mg		Weight	Risk Ratio
	Events	Total	Events	Total		M-H, Fixed, 95% CI
Färkkilä M et al., 2012	53	82	61	71	20.5%	0.75 [0.62, 0.91]
Goadsby PJ et al., 2019	166	654	253	649	79.5%	0.65 [0.55, 0.77]
Total (95% CI)		736		720	100.0%	0.67 [0.59, 0.77]
Total events	219		314			

Heterogeneity: Chi² = 1.57, df = 1 (P = 0.21); I² = 36%
 Test for overall effect: Z = 5.83 (P < 0.00001)

